Post-earnings recap
Reported
Wed, May 27, 2026
EPS actual
$1.49
EPS est.
$1.40
EPS surprise
+6.20%
1-day move
+0.66%
Agilent Technologies reported better-than-expected earnings per share, which contributed to a slight increase in the stock price. However, revenue figures were not disclosed, leaving some uncertainty about overall performance. Investors may view the EPS beat positively, but the lack of revenue data could lead to cautious sentiment moving forward.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.49 | $1.41 | +6.20% |
| Revenue | — | $1.8B | — |
No transcript is on record, and the analysis is based solely on numerical results.
Agilent Technologies, Inc. is a leading player in the health care sector, specifically in life sciences tools and services. The company provides essential instruments and solutions for laboratories, which are crucial for research and development in various scientific fields. As the demand for advanced health care solutions continues to grow, Agilent's role in supporting innovation in diagnostics and pharmaceuticals becomes increasingly important.
Last quarter
In Q1-2026, Agilent reported an EPS of $1.36, slightly missing the estimate of $1.37. The stock reacted positively, gaining 0.26% the next day.
Management promises and guidance
EPS beat streak
2Q
EPS beat rate
75%
Avg EPS surprise
+2.91%
Avg 1-day reaction
+0.42%
Analysts expect Agilent to report solid earnings this quarter, with a consensus EPS of $1.41 and revenue of $1.8 billion. The market is closely watching for any signs of growth in key segments.
Bull case
If Agilent beats earnings expectations and shows strong revenue growth, it could indicate robust demand for its products, leading to a positive stock reaction.
Bear case
Conversely, if the company misses estimates or provides weak guidance, it may raise concerns about its growth prospects, potentially leading to a decline in stock price.
Key metrics to watch
EPS
$1.41Earnings per share is a key indicator of the company's profitability and financial health.
Revenue
$1.8BTotal revenue reflects the company's ability to generate sales and is critical for assessing growth.
The print will turn on these.
Q1
Will Agilent's EPS exceed the consensus estimate of $1.41?
A beat on EPS could signal stronger than expected demand and operational efficiency, which would likely boost investor confidence.
Q2
What are the revenue growth rates in key segments?
Understanding growth in specific areas will help investors gauge the company's future performance and market position.
—
Est. EPS
$1.01
Est. Rev
$543M
Impl. Move
±8.7%
Why consensus could be wrong
The consensus may underestimate Agilent's ability to capitalize on emerging trends in life sciences, particularly in diagnostics and personalized medicine.
Supporting evidence
Agilent has consistently outperformed EPS estimates in 75% of the last eight quarters.
Options pricing suggests a larger expected move than historical averages, indicating heightened investor interest.
The company has a strong track record of innovation, which may not be fully reflected in current estimates.
Key risk
If revenue growth in key segments exceeds expectations, it could significantly alter the current consensus outlook.
Pre-commit to what would confirm each case.
This quarter's performance will be closely watched as it follows a slight miss last quarter, and any significant deviation could impact market sentiment.
Bull confirmed if
An EPS of $1.45 or higher would confirm strong operational performance and demand.
Bear confirmed if
An EPS below $1.39 would raise concerns about the company's growth trajectory.
What the market is pricing for the move.
Implied Move
±6.23%
Historical Avg
±0.5%
The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.
Options are pricing ±4.8% while A has averaged ±0.5% over the last 8 prints — setup is pricing rich.
ATM IV
0.4%
30d HV
34.2%
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options pricing rich in Health Care
Fade rate: 15 of 30 (50%)
This setup has occurred 30 times across Health Care in the last 2 years. 15 of 30 faded and 15 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.9%, with a raw directional average of -1.9% (modestly negative historical bias).
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Agilent beats expectations, history suggests a positive stock reaction, averaging a 0.04% increase on such occasions.
In line / cautious
A result in line with expectations may lead to a muted reaction, with the stock likely reflecting cautious sentiment.
Miss
If the company misses estimates, the stock could see a decline, with historical averages showing a potential drop of around 0.29%.
The lines on the call that would change the story.